Edwards Lifesciences Affirms FY2026 Adj EPS Guidance of $2.95-$3.05 vs $3.01 Est; Raises FY2026 Sales Guidance from $6.500B-$6.900B to $6.600B-$6.900B vs $6.745B Est
Edwards Lifesciences (NYSE:EW) affirms FY2026 Adj EPS guidance from $2.95-$3.05 to $2.95-$3.05 vs $3.01 analyst estimate. Raises FY2026 sales outlook from $6.500 billion-$6.900 billion to $6.600 billion-$6.900 billion
Edwards Lifesciences kept its profit forecast the same but raised the lower end of its sales target, meaning they think they'll sell more stuff next year. When a company raises sales guidance, it suggests their business is doing better than they expected—something to notice when checking if the company is growing.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.